Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 75Carcinoma, Hepatocellular 47Ovarian Neoplasms 40Carcinoma, Non-Small-Cell Lung 26Neoplasms 22Fallopian Tube Neoplasms 17Lung Neoplasms 15Breast Neoplasms 13Neoplasm Metastasis 12Glioblastoma 12Endometrial Neoplasms 12Brain Neoplasms 12Colonic Neoplasms 11Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Uterine Cervical Neoplasms 9Liver Neoplasms 9Stomach Neoplasms 8Colorectal Cancer Metastatic 7Pancreatic Neoplasms 6Advanced Solid Tumors 6Recurrence 5Melanoma 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Ovarian Epithelial 5Biliary Tract Neoplasms 5Solid Tumor 4Meningeal Carcinomatosis 4Adenocarcinoma of Lung 4

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hereditary leiomyomatosis and renal cell cancer × Bevacizumab × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡